<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    16787990
   </pmid>
   <datecreated>
    <year>
     2006
    </year>
    <month>
     09
    </month>
    <day>
     08
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2006
    </year>
    <month>
     10
    </month>
    <day>
     12
    </day>
   </datecompleted>
   <article pubmodel="Print-Electronic">
    <journal>
     <issn issntype="Print">
      0021-972X
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       91
      </volume>
      <issue>
       9
      </issue>
      <pubdate>
       <year>
        2006
       </year>
       <month>
        Sep
       </month>
      </pubdate>
     </journalissue>
     <title>
      The Journal of clinical endocrinology and metabolism
     </title>
     <isoabbreviation>
      J. Clin. Endocrinol. Metab.
     </isoabbreviation>
    </journal>
    <articletitle>
     Neonatal screening for congenital hypothyroidism based on thyroxine, thyrotropin, and thyroxine-binding globulin measurement: potentials and pitfalls.
    </articletitle>
    <pagination>
     <medlinepgn>
      3370-6
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="CONTEXT" nlmcategory="BACKGROUND">
      The Dutch T(4)-TSH-TBG-based neonatal screening program detects patients with congenital hypothyroidism (CH) of thyroidal (CH-T) as well as central (CH-C) origin. The numbers and characteristics of true-positive and false-positive referrals will differ from other, predominantly TSH-based, screening methods.
     </abstracttext>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      The present study describes the characteristics of the referred neonates, both CH patients and false positives, and of the reported CH patients with a false-negative screening result born in the study period. DESIGN, SETTING, PATIENTS, AND MAIN OUTCOME MEASURE: For each referred child born between April 1, 2002, and May 31, 2004, screening results and first venous sample results were recorded and classified as transient or permanent CH-T or CH-C or as no CH.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      In the study period, 430,764 children were screened. Of the 772 children with abnormal screening results, 224 (29%) had CH; another 13 CH patients did not have abnormal screening results, giving an overall CH incidence of 1:1800. Incidences of permanent CH, permanent CH-T, permanent CH-C, and transient CH were 1:2200, 1:2500, 1:21,000, and 1:12,000, respectively. The most frequent explanations for the 548 false-positive referrals (71% of the referred cohort) were severe illness and TBG deficiency (occurring in 198 and 200 children, respectively).
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      The Dutch incidence figures for CH belong to the highest worldwide, suggesting that the T(4)-TSH-TBG screening program is an efficient method to detect CH of variable etiology and severity. Still, a small percentage of children with CH escaped detection via this screening approach. Severe illness and TBG deficiency appear to be responsible for the majority of false-positive referrals.
     </abstracttext>
    </abstract>
    <affiliation>
     Academic Medical Center, University of Amsterdam, G8-205, Emma Children's Hospital AMC, Department of Pediatric Endocrinology, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands. m.j.kempers@amc.uva.nl
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Kempers
      </lastname>
      <forename>
       M J E
      </forename>
      <initials>
       MJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lanting
      </lastname>
      <forename>
       C I
      </forename>
      <initials>
       CI
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       van Heijst
      </lastname>
      <forename>
       A F J
      </forename>
      <initials>
       AF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       van Trotsenburg
      </lastname>
      <forename>
       A S P
      </forename>
      <initials>
       AS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wiedijk
      </lastname>
      <forename>
       B M
      </forename>
      <initials>
       BM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       de Vijlder
      </lastname>
      <forename>
       J J M
      </forename>
      <initials>
       JJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Vulsma
      </lastname>
      <forename>
       T
      </forename>
      <initials>
       T
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
    <articledate datetype="Electronic">
     <year>
      2006
     </year>
     <month>
      06
     </month>
     <day>
      20
     </day>
    </articledate>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     J Clin Endocrinol Metab
    </medlineta>
    <nlmuniqueid>
     0375362
    </nlmuniqueid>
    <issnlinking>
     0021-972X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      7488-70-2
     </registrynumber>
     <nameofsubstance>
      Thyroxine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      9002-71-5
     </registrynumber>
     <nameofsubstance>
      Thyrotropin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      9010-34-8
     </registrynumber>
     <nameofsubstance>
      Thyroglobulin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Congenital Hypothyroidism
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
     <qualifiername majortopicyn="Y">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      False Negative Reactions
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      False Positive Reactions
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Infant, Newborn
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Neonatal Screening
     </descriptorname>
     <qualifiername majortopicyn="Y">
      methods
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N" type="Geographic">
      Netherlands
     </descriptorname>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thyroglobulin
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thyrotropin
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thyroxine
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="aheadofprint">
     <year>
      2006
     </year>
     <month>
      6
     </month>
     <day>
      20
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2006
     </year>
     <month>
      6
     </month>
     <day>
      22
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2006
     </year>
     <month>
      10
     </month>
     <day>
      13
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2006
     </year>
     <month>
      6
     </month>
     <day>
      22
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pii">
     jc.2006-0058
    </articleid>
    <articleid idtype="doi">
     10.1210/jc.2006-0058
    </articleid>
    <articleid idtype="pubmed">
     16787990
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

